Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure

Hepatology

Volumn 24, Issue 6, 1996, Pages 1446-1451

  Ellis, Antony J ^a   Hughes, Robin D ^a   Wendon, Julia A ^a   Dunne, Joseph ^a   Langley, Peter G ^a   Kelly, James H ^b   Gislason, Gardar T ^b   Sussman, Norman L ^b   Williams, Roger ^a,c  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b Hepatix Inc   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GALACTOSE;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOCOMPATIBILITY; BRAIN DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DISSEMINATED INTRAVASCULAR CLOTTING; EXTRACORPOREAL LIVER PERFUSION; FEMALE; HEMOPERFUSION; HUMAN; HYPERSENSITIVITY REACTION; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL;

EID: 0029909765     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.1996.v24.pm0008938179     Document Type: Article

References (24)

1. Jauregui HO, Gann KL. Mammalian hepatocytes as a foundation for treatment in human liver failure. J Cellular Biochem 1991;45:359-365.
2. Nyberg SL, Shatford RA, Hu W-S, Payne WD, Cerra FB. Hepatocyte culture systems for artificial liver support: Implications for critical care medicine (bioartificial liver support). Crit Care Med 1992;20:1157-1168.
3. Sussman NL, Kelly JH. Temporary liver support: theory, practice, predictions. Xeno 1995;3:63-67.
4. Rozga J, Williams F, Ro M-S, Neuzil DF, Giorgio TD, Backfisch G, Moscioni AD, et al. Development of a bioartificial liver: properties and function of a hollow-fibre module innoculated with liver cells. HEPATOLOGY 1993; 17: 258-265.
5. Rozga J, Podesta L, LePage E, Morsiani E, Moscioni AD, Hoffman A, Sher L, et al. A bioartificial liver to treat severe acute liver failure. Ann Surg 1994;219:538-546.
6. Sussman NL, Chong MG, Koussayer T, He D, Shang TA, Whisennand HH, Kelly JH. Reversal of fulminant hepatic failure using an extracorporeal liver assist device. HEPATOLOGY 1992;16:60-65.
7. Gislason GT, Lobdell DD, Kelly JH, Sussman NL. A treatment system for implementing an extracorporeal liver assist device. Artif Organs 1994; 18: 385-389.
8. Sussman NL, Gislason GT, Conlin CA, Kelly JH. The Hepatix extracorporeal liver assist device: initial clinical experience. Artif Organs 1994; 18: 390-396.
9. Kelly JH, Koussayer T, He D, Chong MG, Shang TA, Whisennand HH, Sussman NL. Assessment of an extracorporeal liver assist device in anhepatic dogs. Artif Organs 1992;16:418-422.
10. Kelly JH, Koussayer T, He De, Chong MG, Shang TA, Whisennand HH, Sussman NL. An improved model of acetaminophen-induced fulminant hepatic failure in dogs. HEPATOLOGY 1992;15:329-335.
11. Sussman NL, Kelly JH. Extracorporeal liver assist in the treatment of fulminant hepatic failure. Blood Purif 1993;11:170-174.
12. Sussman NL, Finegold MJ, Barish JP, Kelly JH. A case of syncytial giant-cell hepatitis treated with an extracorporeal liver assist device. Am J Gastroenterology 1994;89:1077-1082.
13. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-445.
14. Ranek L, Buch Andreasen P, Tygstrup N. Galactose elimination capacity as a prognostic index in patients with fulminant hepatic failure. Gut 1976; 17:959-964.
15. Williams R. New directions in acute liver failure. J Roy Coll Phys 1994; 28:552-559.
16. Hughes RD, Williams R. Evaluation of extracorporeal liver assist devices. Liv Transplant Surg 1995;1:200-206.
17. Hughes RD, Cochrane AMG, Thomson AD, Murray-Lyon IM, Williams R. The cytotoxicity of plasma from patients with acute hepatic failure to isolated rabbit hepatocytes. Br J Exp Path 1976;57:348-353.
18. 1 in acute liver failure. Int J Artif Organs 1996;19:240-244.
19. O'Grady JG, Langley PG, Isola LM, Aledort LM, Williams R. Coagulopathy of fulminant hepatic failure. Semin Liv Dis 1986;6:159-163.
20. Silk DBA, Williams R. Experiences in the treatment of fulminant hepatic failure by conservative therapy, charcoal haemoperfusion, and polyacrylonitrile haemodialysis. Int J Artif Organs 1978;1:29-33.
21. Weston MJ, Langley PG, Rubin MH, Hanid MA, Mellon PJ, Williams R. Platelet function in fulminant hepatic failure and effect of charcoal haemoperfusion. Gut 1977;18:897-902.
22. Sette H, Hughes RD, Langley PG, Gimson AES, Williams R. Heparin response and clearance in acute and chronic liver disease. Thromb Haemost 1985;54:591-594.
23. Herbelin A, Nguyen AT, Zingraff J, Urena P, Descamps-Latscha B. Influence of uremia and haemodialysis on circulating interleukin-1 and tumor necrosis factor a. Kidney Int 1990;37:116-125.
24. Craddock PR, Fehr J, Dalmasso AP, Brighan KL, Jacob HS. Pulmonary vascular leukostasis resulting from complement activation by dialyser cellophane membranes. J Clin Invest 1977;59:879-888.